REGN Regeneron Pharmaceuticals, Inc.: Earnings per share for the last 12 months

The annual net income per share TTM growth rate for Regeneron Pharmaceuticals (REGN) reflects the success of Dupixent and Eylea, with the latest value recorded as 8.30. Business resilience is based on inelastic demand and patents, despite the risks of their expiration. The company is currently reducing its dependence on its primary blockbusters by actively developing genetic research and the oncology sector.
REGN (Regeneron): analytical breakdowns and indicator data

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net profit per share, comparing current returns with the previous year to evaluate the effectiveness of business expansion. By analyzing the current EPS YoY TTM growth trend, an investor can see the real return on invested capital. This indicator reflects the company's ability to generate profit above the baseline. For Regeneron Pharmaceuticals (REGN), this is a critical marker of resilience against biosimilar expansion and the risk of dependence on a single flagship drug.